Arcutis Biotherapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Arcutis Biotherapeutics has a total shareholder equity of $186.4M and total debt of $203.8M, which brings its debt-to-equity ratio to 109.3%. Its total assets and total liabilities are $444.8M and $258.3M respectively.
Belangrijke informatie
109.3%
Verhouding schuld/eigen vermogen
US$203.81m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$362.44m |
| Aandelen | US$186.43m |
| Totaal verplichtingen | US$258.33m |
| Totaal activa | US$444.76m |
Recente financiële gezondheidsupdates
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17
Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Recent updates
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Analyse van de financiële positie
Kortlopende schulden: ARQT's short term assets ($434.6M) exceed its short term liabilities ($51.4M).
Langlopende schulden: ARQT's short term assets ($434.6M) exceed its long term liabilities ($207.0M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ARQT has more cash than its total debt.
Schuld verminderen: ARQT's debt to equity ratio has increased from 0% to 109.3% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: ARQT has sufficient cash runway for more than a year based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if ARQT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.